Conclusions
In patients with stable HFrEF, dapagliflozin led to a significant short-term reduction of CA125 but not NT-proBNP. Changes in CA125 mediated the effect on the short-term maximal functional capacity. Further studies are warranted to confirm these findings in this and other HF clinical scenarios.